You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Références<br />
141. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy<br />
in adults infected with human immunodeficiency virus and the ro<strong>le</strong> of hepatitis C or B virus infection. Jama.<br />
2000 Jan 5;283(1):74-80.<br />
142. Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with<br />
indinavir. Lancet. 1997 Mar 29;349(9056):924-5.<br />
143. Matsuda J, Gohchi K. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir.<br />
Lancet. 1997 Aug 2;350(9074):364.<br />
144. Arribas JR, Ibanez C, Ruiz-Antoran B, Pena JM, Esteban-Calvo C, Frias J, et al. Acute hepatitis in HIVinfected<br />
patients during ritonavir treatment. Aids. 1998 Sep 10;12(13):1722-4.<br />
145. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity<br />
associated with antiretroviral combination therapy. J Infect Dis. 2002 Jul 1;186(1):23-31.<br />
146. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease<br />
inhibitor-based antiretroviral regimens with or without concurrent ritonavir. Aids. 2004 Nov 19;18(17):2277-<br />
84.<br />
147. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive<br />
patients. Aids. 1993 Mar;7(3):379-85.<br />
148. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, et al. Fulminant hepatitis with severe<br />
lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med. 1994 Apr;235(4):367-71.<br />
149. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, et al. Zidovudineinduced<br />
mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial<br />
DNA dep<strong>le</strong>tion. J Hepatol. 1999 Jan;30(1):156-60.<br />
150. ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of<br />
lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS. 2000 Sep;11(9):611-<br />
6.<br />
151. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected<br />
patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect<br />
Dis. 2000 Nov;31(5):1234-9.<br />
152. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nuc<strong>le</strong>oside<br />
analogue reverse-transcriptase inhibitors. Aids. 2002 Nov 8;16(16):2165-73.<br />
153. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs<br />
standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized<br />
control<strong>le</strong>d trial. JAMA. 2004;292:2839-48.<br />
154. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus<br />
ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J<br />
Med. 2004;351:451-9.<br />
155. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonza<strong>le</strong>z-García J, Lazzarin A, et al. Peginterferon<br />
Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med.<br />
2004;351:438-50.<br />
156. Mira JA, Va<strong>le</strong>ra-Bestard B, Arizcorreta-Yarza A, Gonza<strong>le</strong>z-Serrano M, Torre-Cisneros J, Santos I, et al.<br />
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among<br />
HIV/HCV-coinfected patients. Antivir Ther. 2007;12(4):523-9.<br />
157. Martin-Carbonero L, Nunez M, Marino A, Alcocer F, Bonet L, Garcia-Samaniego J, et al. Undetectab<strong>le</strong><br />
hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic<br />
hepatitis C. Aids. 2008 Jan 2;22(1):15-21.<br />
158. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV<br />
coinfection. Lancet. 2001 Jan 27;357(9252):280-1.<br />
159. Laguno M, Milinkovic A, de Lazzari E, Murillas J, Martinez E, Blanco JL, et al. Incidence and risk factors for<br />
mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther. 2005;10(3):423-9.<br />
160. Harvie P, Omar RF, Dusserre N, Lansac N, Desormeaux A, Gourde P, et al. Ribavirin potentiates the efficacy<br />
and toxicity of 2',3'- dideoxyinosine in the murine acquired immunodeficiency syndrome model. J Pharmacol<br />
Exp Ther. 1996 Nov;279(2):1009-17.<br />
161. K<strong>le</strong>in MB, Campeol N, Lalonde RG, Brenner B, Wainberg MA. Didanosine, interferon-alfa and ribavirin: a<br />
highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. Aids. 2003 May<br />
2;17(7):1001-8.<br />
162. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial<br />
dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G193-9.<br />
163. B Guiu. Stéatose hépatique et séquence phase- opposition de phase : aspects théoriques et applications<br />
pratiques à 3T. Journal de Radiologie. 2007;88:1845-53.<br />
164. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM. Different mechanisms of steatosis in<br />
hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat. 2004 Sep;11(5):455-8.<br />
165. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of<br />
steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005 Jul;54(7):1003-8.<br />
183
Change language